Le Lézard
Classified in: Health
Subject: FDA

Soom Launches Mobile App That Notifies Patients, Caregivers and Nurses of Medical Device Recalls


BOSTON, July 15, 2019 /PRNewswire/ --  Soom, a pioneer in utilizing barcode and knowledge graph technologies to bridge information gaps between data sources and physical products, has introduced SoomSafety, an iOS mobile app that allows users to scan a medical device and receive instructions for use, safety and recall information directly from the device manufacturer and U.S. Food and Drug Administration (FDA).

Soom, a pioneer in utilizing barcode and knowledge graph technologies to bridge information gaps between data sources and physical products, has introduced SoomSafety, an iOS mobile app that allows users to scan a medical device and receive instructions for use, safety and recall information directly from the device manufacturer and U.S. Food and Drug Administration (FDA).

"We built SoomSafety to help patients and caregivers relying on implanted medical devices and using medical devices at home answer one critical question, 'Is this medical device safe to use?'" said Charlie Kim, President and CEO of Soom. "Our technology makes it possible to connect previously siloed medical device data, giving patients?and their caregivers?more proactive control over their health and safety."

SoomSafety is the first app to utilize openFDA, open-source databases that enable developers to quickly and easily use FDA data in applications. "This year alone, 26 medical device products have been recalled, affecting nearly 50 million individual devices in the United States." According to Kim, many patients are never informed of these recalls due to incomplete information in the medical device supply chain. Soom is empowering patients and caregivers to proactively manage their medical devices for improved patient outcomes and peace of mind.

SoomSafety users scan the barcode on a medical device, such as an insulin pump, nebulizer or apnea monitor, to automatically identify the device and store it in the app. The app also identifies and stores implanted medical devices like artificial joints, pacemakers and heart valves by scanning the barcode on a patient's medical device identification card.

Once a device is stored, the app checks for FDA recall information, provides next steps in the event of a recall and pushes notifications if the device is ever recalled. In addition, the app displays safety and use information for each stored device.

The idea for SoomSafety was prompted by Kim's personal experience with a medical device recall that threatened the life of his youngest daughter.

"I've experienced first-hand what it feels like to wonder if a medical device that your loved one uses?relies on?is safe," said Kim. "It's a feeling that no patient, parent or caregiver should have to endure. That's why at Soom we're dedicated to finding new ways to use technology to ensure clarity and confidence in the medical devices we use."

SoomSafety is available now for free in the Apple App Store. Patients, caregivers and homecare professionals can learn more about SoomSafety at www.soom.com/soomsafety.

About Soom
Soom uses proven technology and science to enable interoperability, safety, collaboration and efficiency throughout the healthcare value chain. Headquartered in Boston, with offices worldwide, and a pioneer in the industry, we offer a cloud-based enterprise SaaS platform that provides the healthcare industry with a simple solution that enables master data accuracy, data governance, error correction, and, ultimately, improved patient safety. The Soom platform is a powerful knowledge graph connecting siloed databases and is compliant with GS1 standards and global UDI regulations. For more information, visit www.Soom.com or follow us on Twitter, LinkedIn and Facebook.

SOURCE Soom


These press releases may also interest you

at 22:31
CStone Pharmaceuticals ("CStone" or the "Company", HKEX: 2616) updated results from the CS1001-201 trial in a poster presentation at the 2019 American Society of Hematology (ASH) Annual Meeting. CS1001-201 trial is a single-arm, multicenter Phase II...

at 21:07
Following the release of details from a surprise billing agreement between Senate Health, Education, Labor and Pensions (HELP) Committee Chairman Lamar Alexander (R-TN) and House Energy and Commerce Committee Chairman Frank Pallone Jr. (D-NJ) and...

at 21:05
Aurinia Pharmaceuticals Inc. ("Aurinia" or the "Company"), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today announced the pricing of its underwritten public offering of 11,115,165...

at 20:00
A team led by Stavros Zanos, MD, PhD, assistant professor at the Feinstein Institutes for Medical Research, has published an overview of how bioelectronic medicine may be used to treat pulmonary arterial hypertension (PAH) in the Springer Nature...

at 19:50
North Bud Farms Inc. ("NORTHBUD" or the "Company") is pleased to announce the appointments of Mr. Ryan Brown as Executive Chairman of the Board of Directors, Mrs. Jennifer Ross-Carriere to the Board of Directors and Mr. Sean Homuth as Chief...

at 19:45
UCB, a global biopharmaceutical company, today announced positive results from a Phase II study (TP0001; NCT02718716) of its novel, first-in-class subcutaneous (SC, under the skin) monoclonal antibody, rozanolixizumab, in patients with primary immune...



News published on 15 july 2019 at 08:57 and distributed by: